Home » Posts tagged 'Novus Communications'
Tag Archives: Novus Communications
Brand Comms CEO Alan Green catches up once again with Blencowe Resources #BRES CEO Mike Ralston.
Mike provides a background on the latest developments at the company’s 100% owned Orom Cross Graphite project in Uganda. We look at the preliminary assay metallurgy test results, before Mike updates on the fully funded Phase 2 drilling campaign.
Mike looks at how the growth in the lithium ion battery and EV market is driving demand for graphite, before providing investors with a milestone route map for the next few months.
Alan Green talks to Malcolm Palle, Executive Chairman of Coinsilium (AQX: #COIN, OTCQB: $CINGF), a Blockchain & Open Finance venture builder based in Gilbratar.
Malcolm traces the history of Coinsilium as the first ever blockchain IPO on the Aquis market, through to the move to Gilbraltar and last year’s pivot to become a venture builder in the blockchain and Non Fungible Token space.
We discuss the nebulous opportunities available across the NFT market, with examples of digital art by Beeple and the Kings of Leon album release as an NFT.
Malcolm then covers the company finances before providing some key takeaway points and milestones for investors.
Alan Green talks to David Bramhill, Executive Chairman at Union Jack Oil (AIM: UJO), a company engaged in onshore hydrocarbon production and development in the UK.
David discusses progress at key projects including West Newton, Wressle, Biscathorpe and Keddington before we look at the acquisition of the Piper Complex Royalty Units from Cambridge Petroleum announced today.
David discuses the recent share consolidation before we take a look at the what the year ahead holds for Union Jack Oil.
Alan Green talks to David Bramhill, Executive Chairman at Union Jack Oil (AIM: UJO), a company engaged in onshore hydrocarbon production and development in the UK. David discusses key projects including Wressle and the additional stake acquisition which takes the UJO stake to 45.5%. He also discusses West Newton and Biscathorpe, and with over £5m in the company kitty, he provides a bullish outlook for the oil price. David looks at value inflection points for the company as we emerge from the COVID crisis, and provides key takeaway points for investors.
Alan Green talks to Mike Ralston, CEO of Blencowe Resources (LON: BRES) about the company’s 100% owned Orom Graphite Project
Brand Comms CEO Alan Green talks to Mike Ralston, CEO of Blencowe Resources (LON: BRES) about the company’s 100% owned Orom Graphite Project in Uganda. Mike explains the rationale behind what is a huge project in scale, the low extraction costs and the quality of the ‘jumbo flake’ graphite. He touches on the company structure and provides takeaway points for investors.
Alan Green of Novus Communications talks to Nick Lee, Director of Pires Investments (AIM: PIRI). Nick discusses the FY results out today, the profits hike, the £1m fundraising plus the recent involvement of technology investor Chris Akers. Nick discusses the technology companies that Pires has invested into, and finishes with three key takeaway points for investors.
Vincent Mascolo, CEO of AIM listed IronRidge Resources (AIM: IRR) joins Alan Green of Novus Communications to talk about today’s update on the Zaranou Gold Project on the Ivory Coast. Vincent also covers the latest developments across the company’s other projects including the Ewoyaa Lithium Project, and provides three key takeaway points for investors.
LocoSoco Group Plc, the Wiener Borse traded company that builds technology to profit from creating sustainable communities, announces the issue of 30,000 new ordinary shares at £1 per share to Novus Communications Ltd in part settlement of an agreement to provide investor relations services.
The Company also issues 1,000,000 new ordinary shares at 25p per share to William John (HV) plc as a result of their exercise of warrants.
Following the issue of shares, the Company announces that in accordance with Financial Conduct Authority’s Disclosure and Transparency Rules (“DTRs”), the total issued share capital of the Company with voting rights is 13,863,733 ordinary shares.
LocoSoco Group PLC
James Perry, Chief Executive Officer
Simon Rendell, Non-Executive Chairman
+44 (0)203 538 0716
Novus Communications Ltd
Alan Green / Jacqueline Briscoe
+44 (0)7976 431608 / +44 (0)207 448 9839
Keswick Global AG – Capital Market Coach
Tim Curle, Klaus Schwerdtfeger
email@example.com / +43 (1)740 408045
About LocoSoco Group Plc
LocoSoco builds technology to profit from creating sustainable communities. We work with community partners to turn community assets into eco-enterprises enabling them to generate additional revenues whilst going green.
Community partners have the opportunity to engage with their local community on sustainability, whilst also earning additional revenue for themselves, their businesses and causes.
LocoSoco Group Plc listed on the Austrian Wiener Borse Direkt Market in February 2019.
Brand CEO Alan Green talks about: Metro Bank #MTRO Cadence Minerals #KDNC and Smart Metering Systems #SMS on the Vox Podcast.
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director.
David has extensive orphan drug company experience both in Europe and in the USA. He was Executive Vice President and Managing Director of Ireland at Horizon Therapeutics plc, a biopharmaceutical company listed on Nasdaq and headquartered in Dublin. David has an excellent combination of experience having worked in larger product focussed pharmaceutical companies and also in turning around smaller pharmaceutical companies. For example, he and his colleagues transformed AGI Therapeutics before selling it to Vidara Therapeutics which in turn was acquired by Horizon Therapeutics plc, a company with a current market capitalisation of $4.5 billion.
David also served as Senior Vice President of Warner Chilcott, a fully integrated specialty pharmaceutical company. While at Warner Chilcott, he led the company’s successful IPO on Nasdaq. In addition, David also held roles in Elan Corporation and KPMG.
With David joining the Board and following the completion of the Company’s acquisition of Open Orphan DAC, Tony Richardson has stepped down from the Board with effect from today. The Company would like to thank him for his service as a Director.
Professor Brendan Buckley, Chairman, Open Orphan, commented:
“We are delighted that David is joining the Board of Open Orphan. He has extensive experience in the orphan drug market and we are looking forward to having David work closely with management going forward as we seek to rapidly grow the company.”
The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies and paragraph (g) of Schedule Two of the Euronext Growth Rules for Companies:
Full name: David George Kelly
Current Directorships / Partnerships: Iterum Therapeutics plc, Iterum Therapeutics International Limited, Andromeda Biotech Limited, Horizon Pharma Israel Holding Corp. Limited, Horizon Pharma Investment Limited, Horizon Pharma Ireland Limited.
Past Directorships / Partnerships (past 5 years): Horizon Pharma GMBH, Horizon Pharma Rheumatology Limited, Horizon Pharma Switzerland GMBH, Horizon Pharma Finance S.A.R.L, Horizon Pharma Services Limited, Horizon Pharma Finance Limited, Horizon Pharma Holdings 2 Limited, Hyperion Therapeutics Ireland Operating Limited, Hyperion Therapeutics Ireland Holdings Limited, Horizon Pharma Treasury Limited, Horizon Pharma Holdings Limited, Horizon Pharma Capital Limited, Hyperion Therapeutics International Operating Limited, Hyperion Therapeutics International Holdings Limited, Horizon Therapeutics plc, Horizon Pharma Aon Limited, Horizon Pharma Trí Limited, Horizon Pharma Dó Limited.
Open Orphan Plc Tel: +353 (0)1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.